New weapon tested to attack prostate cancer before surgery
NCT ID NCT06014255
Summary
This study is testing if a new drug called enoblituzumab, given for 12 weeks before prostate removal surgery, can help men with high-risk prostate cancer. The goal is to see if this approach helps keep the cancer from coming back better than standard care alone. Researchers will compare outcomes like cancer recurrence and survival between the two groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Northewestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Minnesota
NOT_YET_RECRUITINGMinneapolis, Minnesota, 55414, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
XCancer - Omaha, LLC
NOT_YET_RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.